Journal of Applied Physiology Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 84: 1646-1652, 1998;
8750-7587/98 $5.00
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klinger, J. R.
Right arrow Articles by Hill, N. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klinger, J. R.
Right arrow Articles by Hill, N. S.
Vol. 84, Issue 5, 1646-1652, May 1998

Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats

James R. Klinger, Rod R. Warburton, Linda Pietras, and Nicholas S. Hill

Division of Pulmonary and Critical Care Medicine, Rhode Island Hospital and Brown University School of Medicine, Providence, Rhode Island 02903

Brain natriuretic peptide (BNP) is a pulmonary vasodilator that is elevated in the right heart and plasma of hypoxia-adapted rats. To test the hypothesis that BNP protects against hypoxic pulmonary hypertension, we measured right ventricular systolic pressure (RVSP), right ventricle (RV) weight-to-body weight (BW) ratio (RV/BW), and percent muscularization of peripheral pulmonary vessels (%MPPV) in rats given an intravenous infusion of BNP, atrial natriuretic peptide (ANP), or saline alone after 2 wk of normoxia or hypobaric hypoxia (0.5 atm). Hypoxia-adapted rats had higher hematocrits, RVSP, RV/BW, and %MPPV than did normoxic controls. Under normoxic conditions, BNP infusion (0.2 and 1.4 µg/h) increased plasma BNP but had no effect on RVSP, RV/BW, or %MPPV. Under hypoxic conditions, low-rate BNP infusion (0.2 µg/h) had no effect on plasma BNP or on severity of pulmonary hypertension. However, high-rate BNP infusion (1.4 µg/h) increased plasma BNP (69 ± 8 vs. 35 ± 4 pg/ml, P < 0.05), lowered RV/BW (0.87 ± 0.05 vs. 1.02 ± 0.04, P < 0.05), and decreased %MPPV (60 vs. 74%, P < 0.05). There was also a trend toward lower RVSP (55 ± 3 vs. 64 ± 2, P = not significant). Infusion of ANP at 1.4 µg/h increased plasma ANP in hypoxic rats (759 ± 153 vs. 393 ± 54 pg/ml, P < 0.05) but had no effect on RVSP, RV/BW, or %MPPV. We conclude that BNP may regulate pulmonary vascular responses to hypoxia and, at the doses used in this study, is more effective than ANP at blunting pulmonary hypertension during the first 2 wk of hypoxia.

pulmonary circulation; anoxia; atrial natriuretic peptide; brain natriuretic peptide


This article has been cited by other articles:


Home page
 ChestHome page
J. R. Klinger, S. Thaker, J. Houtchens, I. R. Preston, N. S. Hill, and H. W. Farber
Pulmonary hemodynamic responses to brain natriuretic Peptide and sildenafil in patients with pulmonary arterial hypertension.
Chest, February 1, 2006; 129(2): 417 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
I. R. Preston, N. S. Hill, R. R. Warburton, and B. L. Fanburg
Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation
Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L367 - L374.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
K. M. O'Dell, J. S. Kalus, S. Kucukarslan, and B. Czerska
Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure
Am. J. Health Syst. Pharm., March 15, 2005; 62(6): 606 - 609.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. B. Yap, D. Mukerjee, P. M. Timms, H. Ashrafian, and J. G. Coghlan
Natriuretic Peptides, Respiratory Disease, and the Right Heart
Chest, October 1, 2004; 126(4): 1330 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. R. Klinger, R. R. Warburton, L. Pietras, P. Oliver, J. Fox, O. Smithies, and N. S. Hill
Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy
Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H58 - H65.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath
Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication
Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J.-Z. Sun, S.-J. Chen, G. Li, and Y.-F. Chen
Hypoxia reduces atrial natriuretic peptide clearance receptor gene expression in ANP knockout mice
Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L511 - L519.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
H. Kraiczi, J. Magga, X. Y. Sun, H. Ruskoaho, X. Zhao, and J. Hedner
Hypoxic pressor response, cardiac size, and natriuretic peptides are modified by long-term intermittent hypoxia
J Appl Physiol, December 1, 1999; 87(6): 2025 - 2031.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. R. Klinger, R. R. Warburton, L. A. Pietras, O. Smithies, R. Swift, and N. S. Hill
Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice
Am J Physiol Lung Cell Mol Physiol, May 1, 1999; 276(5): L868 - L874.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online